- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07613710
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Email contact via H. Lundbeck A/S
- Telefonnummer: +45 36301311
- E-Mail: HQ_Medinfo@Lundbeck.com
Studienorte
-
-
-
Helsinki, Finnland, 00380
- Rekrutierung
- Terveystalo Helsinki, Sleep Clinic
-
Turku, Finnland, 20520
- Abgeschlossen
- CRST, Clinical Research Services Turku
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Key Inclusion Criteria:
For all participants in any trial Part (A, B, C and D):
- The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.
Specifically for participants in trial Part A, B, and D:
- The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m^2) at the Screening Visit.
- The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight.
- The participant is ≥18 and ≤55 years of age at the Screening Visit.
Specifically for participants in trial Part C:
- The participant has a BMI ≥18.5 and ≤35 kg/m^2 at the Screening Visit.
- The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis >3 months prior to the Screening Visit.
- The participant is ≥18 and ≤64 years of age at the Screening Visit.
Key Exclusion Criteria:
For all participants in any trial Part (A, B, C and D):
- The participant has previously been enrolled in this trial.
- The participant has previously been dosed with Lu AH69593.
- The participant has participated in a clinical trial <30 days prior to the Screening Visit.
- The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.
- The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of investigational medicinal product (IMP).
- The participant has worked shifts, including night duty, or has travelled across >3 time zones <2 weeks prior to the first dose of IMP.
- The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level.
Specifically for participants in trial Part A, B and D:
- The participant has had a clinically significant illness from which he/she recovered <4 weeks prior to the first dose of IMP.
Specifically for Participants in trial Part B and C:
- The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1.
Specifically for participants in trial Part C:
- The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance.
- The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS).
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Part A (Single Ascending Dose [SAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive single oral dose of Lu AH69593 or placebo.
|
Placebo wird gemäß dem in der Armbeschreibung angegebenen Zeitplan verabreicht.
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimental: Part B (Multiple Ascending Dose [MAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive Lu AH69593 or placebo orally for 10 days.
|
Placebo wird gemäß dem in der Armbeschreibung angegebenen Zeitplan verabreicht.
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimental: Part C (MAD in Participants With Narcolepsy Type 1 [NT1]): Lu AH69593
Participants will receive Lu AH69593 orally for 84 days.
|
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimental: Part D (Food Effect in Healthy Participants): Lu AH69593
Participants with receive two single oral doses of Lu AH69593 in fasting or fed condition.
|
Lu AH69593 will be administered per schedule specified in the arm description.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Baseline up to Day 90
|
Baseline up to Day 90
|
|
Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)
Zeitfenster: Baseline up to Day 84
|
Baseline up to Day 84
|
|
Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to Stimuli
Zeitfenster: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
PVT Parameter - Change From Baseline in Number of Errors of Omission
Zeitfenster: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)
Zeitfenster: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Zeitfenster: Baseline up to Day 90
|
Baseline up to Day 90
|
|
Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593
Zeitfenster: Up to 84 days
|
Up to 84 days
|
|
Maximum Observed Plasma Concentration (Cmax) of Lu AH69593
Zeitfenster: Up to 84 days
|
Up to 84 days
|
|
Time to Reach Cmax (Tmax) of Lu AH69593
Zeitfenster: Up to 84 days
|
Up to 84 days
|
|
AUC From Time Zero to Infinity (AUC0-inf)
Zeitfenster: Up to 6 days
|
Up to 6 days
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Email contact via H. Lundbeck A/S, H. Lundbeck A/S
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20653A
- 2024-511073-29-00 (Ctis)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .